Visual Recovery Time in Patients with Ethambutol-induced Toxic Optic Neuropathy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We aimed to investigate the visual recovery time in patients with ethambutol-induced toxic optic neuropathy (EON) and identify the factors associated with the visual recovery time. Methods: In this retrospective cohort study, we reviewed the medical records of 35 eyes from 35 patients with EON. Visual recovery was defined as a gain of three or more lines from the nadir. Results: Patients were observed following discontinuation of ethambutol (EMB), with the mean follow-up period of 21.0 ± 16.0 months. The visual acuity at nadir was logarithm of the minimum angle of resolution 1.4 ± 0.4, and the final visual acuity was logarithm of the minimum angle of resolution 0.6 ± 0.5. Twenty-seven eyes (77.1%) showed significant visual recovery. In Kaplan-Meier survival, the mean estimated time for visual recovery was 15.2 ± 3.0 months, and 50% of the patients experienced visual recovery at 8.3 ± 2.2 months following EMB discontinuation. Multivariate Cox regression analysis identified several significant risk factors for delayed visual recovery, including duration of EMB medication ≤6 months, period from symptom onset to EMB discontinuation >14 days, and baseline peripapillary retinal nerve fiber layer thickness >98 μm. Conclusions: Our study indicated a mean time of visual recovery of 15 months for EON cases. Therefore, patients diagnosed with EON should be followed up for more than 1 to 2 years to evaluate their visual recovery. Delayed EMB discontinuation, short duration of EMB use, and initial peripapillary retinal nerve fiber layer thickening were associated with delayed visual recovery. Therefore, patients taking EMB should be followed up regularly for early detection of EON and immediate discontinuation of EMB to prevent severe damage to the optic nerve.
Abstract
Purpose: We aimed to investigate the visual recovery time in patients with ethambutol-induced toxic optic neuropathy (EON) and identify the factors associated with the visual recovery time. Methods: In this retrospective cohort study, we reviewed the medical records of 35 eyes from 35 patients with EON. Visual recovery was defined as a gain of three or more lines from the nadir. Results: Patients were observed following discontinuation of ethambutol (EMB), with the mean follow-up period of 21.0 ± 16.0 months. The visual acuity at nadir was logarithm of the minimum angle of resolution 1.4 ± 0.4, and the final visual acuity was logarithm of the minimum angle of resolution 0.6 ± 0.5. Twenty-seven eyes (77.1%) showed significant visual recovery. In Kaplan-Meier survival, the mean estimated time for visual recovery was 15.2 ± 3.0 months, and 50% of the patients experienced visual recovery at 8.3 ± 2.2 months following EMB discontinuation. Multivariate Cox regression analysis identified several significant risk factors for delayed visual recovery, including duration of EMB medication ≤6 months, period from symptom onset to EMB discontinuation >14 days, and baseline peripapillary retinal nerve fiber layer thickness >98 μm. Conclusions: Our study indicated a mean time of visual recovery of 15 months for EON cases. Therefore, patients diagnosed with EON should be followed up for more than 1 to 2 years to evaluate their visual recovery. Delayed EMB discontinuation, short duration of EMB use, and initial peripapillary retinal nerve fiber layer thickening were associated with delayed visual recovery. Therefore, patients taking EMB should be followed up regularly for early detection of EON and immediate discontinuation of EMB to prevent severe damage to the optic nerve.
참고문헌 (24)
- Lee EJ, "Incidence and clinical features of ethambutol-induced optic neuropathy in Korea", J Neuroophthalmol, 28, pp.269~277 (2008)
- Chen HY, "Ethambutol-induced optic neuropathy : a nationwide population-based study from Taiwan", Br J Ophthalmol, 96, pp.1368~1371 (2012)
- Chen SC, "Incidence and prognostic factor of ethambutol-related optic neuropathy : 10-year experience in southern Taiwan", Kaohsiung J Med Sci, 31, pp.358~362 (2015)
- Leibold JE, "The ocular toxicity of ethambutol and its relation to dose", Ann N Y Acad Sci, 135, pp.904~909 (1966)
- Bobrowitz ID, "Ethambutol in the retreatment of pulmonary tuberculosis", Ann N Y Acad Sci, 135, pp.796~822 (1966)
- Pyle MM, "Ethambutol in the retreatment and primary treatment of tuberculosis : a four-year clinical investigation", Ann N Y Acad Sci, 135, pp.835~845 (1966)
- Yang HK, "Incidence of toxic optic neuropathy with low-dose ethambutol", Int J Tuberc Lung Dis, 20, pp.261~264 (2016)
- Talbert Estlin KA, "Risk factors for ethambutol optic toxicity", Int Ophthalmol, 30, pp.63~72 (2010)
- Russo PA, "Toxic optic neuropathy associated with ethambutol : implications for current therapy", J Am Optom Assoc, 65, pp.332~338 (1994)
- Ezer N, "Incidence of ethambutol-related visual impairment during treatment of active tuberculosis", Int J Tuberc Lung Dis, 17, pp.447~455 (2013)
- Kumar A, "Ocular ethambutol toxicity : is it reversible?", J Clin Neuroophthalmol, 13, pp.15~17 (1993)
- Tsai RK, "Reversibility of ethambutol optic neuropathy", J Ocul Pharmacol Ther, 13, pp.473~477 (1997)
- Ambika S, "Visual outcomes of toxic optic neuropathy secondary to Ethambutol:a retrospective observational study from India, an endemic country", Indian J Ophthalmol, 70, pp.3388~3392 (2022)
- Lee JY, "Ganglion cell layer and inner plexiform layer as predictors of vision recovery in ethambutol-induced optic neuropathy : a longitudinal OCT analysis", Invest Ophthalmol Vis Sci, 59, pp.2104~2109 (2018)
- Sheng WY, "Analysis of structural injury patterns in peripapillary retinal nerve fibre layer and retinal ganglion cell layer in ethambutol-induced optic neuropathy", BMC Ophthalmol, 21, pp.132~ (2021)
- Srithawatpong S, "Factors affecting visual recovery in patients with ethambutol-induced optic neuropathy", Clin Ophthalmol, 17, pp.545~554 (2023)
- Chamberlain PD, "Ethambutol optic neuropathy", Curr Opin Ophthalmol, 28, pp.545~551 (2017)
- Chaitanuwong P, "Incidence, risk factors and ophthalmic clinical characteristic of ethambutol-induced optic neuropathy: 7-year experience", Front Ophthalmol, 3, pp.1152215~ (2023)
- Han J, "Longitudinal analysis of retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in ethambutol-induced optic neuropathy", Graefes Arch Clin Exp Ophthalmol, 253, pp.2293~2299 (2015)
- Jin KW, "Longitudinal evaluation of visual function and structure for detection of subclinical ethambutol-induced optic neuropathy", PLoS One, 14, pp.e0215297~ (2019)
- Kozak SF, "The role of copper on ethambutol’s antimicrobial action and implications for ethambutol-induced optic neuropathy", Diagn Microbiol Infect Dis, 30, pp.83~87 (1998)
- Barboni P, "Natural history of Leber’s hereditary optic neuropathy : longitudinal analysis of the retinal nerve fiber layer by optical coherence tomography", Ophthalmology, 117, pp.623~627 (2010)
- Zhang Y, "Characterization of retinal nerve fiber layer thickness changes associated with Leber’s hereditary optic neuropathy by optical coherence tomography", Exp Ther Med, 7, pp.483~487 (2014)
- Moon Y, "Clinical and optic disc characteristics of patients showing visual recovery in Leber hereditary optic neuropathy", J Neuroophthalmol, 40, pp.15~21 (2020)